The Pulmonary Disease Faculty of the Hospital of Buch near Berlin has begun a large-scale study involving approximately 1,000 lung cancer patients to determine the effectiveness of AMDL Inc's DR-70 Tumor Marker. Results are expected in February 2003.

The Hospital of Buch, which is a leading research hospital, is utilized by the faculty of the well-known Medical School of Humbold University of Berlin and the highly acclaimed Charitee Hospital of Berlin for all pulmonary disease cases, including lung cancer, bronchitis and pneumonia. DR-70 has shown in other clinical trials to be an effective screening device for the early detection of 13 different types of cancer with a particularly high degree of sensitivity and accuracy when checking for lung cancer. The technology is currently approved in Canada for the detection and monitoring of lung cancer and is also marketed in the United Kingdom.

The study will determine the usefulness of DR-70 in screening smokers and in monitoring those already diagnosed with lung cancer. AMDL Inc is a developer and marketer of tests for the early detection and monitoring of cancer and other serious diseases.